Legacy Wealth Asset Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-2,511
Closed -$315K 363
2025
Q2
$315K Buy
2,511
+91
+4% +$11.3K 0.08% 312
2025
Q1
$331K Buy
2,420
+591
+32% +$84.5K 0.09% 288
2024
Q4
$280K Sell
1,829
-347
-16% -$58.5K 0.08% 314
2024
Q3
$422K Buy
2,176
+86
+4% +$18K 0.11% 270
2024
Q2
$485K Buy
2,090
+92
+5% +$20K 0.14% 232
2024
Q1
$431K Buy
1,998
+77
+4% +$18K 0.12% 253
2023
Q4
$497K Sell
1,921
-10
-0.5% -$2.46K 0.16% 225
2023
Q3
$496K Buy
1,931
+32
+2% +$8.56K 0.18% 198
2023
Q2
$541K Sell
1,899
-2,000
-51% -$595K 0.19% 187
2023
Q1
$1.08M Sell
3,899
-47
-1% -$13K 0.39% 73
2022
Q4
$1.09M Sell
3,946
-147
-4% -$41.5K 0.42% 70
2022
Q3
$1.09M Buy
4,093
+814
+25% +$173K 0.48% 60
2022
Q2
$669K Buy
3,279
+70
+2% +$14.3K 0.27% 144
2022
Q1
$676K Buy
3,209
+412
+15% +$89.6K 0.24% 157
2021
Q4
$671K Buy
2,797
+296
+12% +$76.1K 0.23% 161
2021
Q3
$708K Buy
2,501
+13
+0.5% +$4.26K 0.32% 129
2021
Q2
$862K Buy
2,488
+82
+3% +$24.8K 0.38% 98
2021
Q1
$673K Buy
2,406
+78
+3% +$21K 0.31% 137
2020
Q4
$570K Buy
+2,328
New +$601K 0.29% 142

Other funds holding BIIB

Legacy Wealth Asset Management's BIIB Position: Q3 2025 in Review

Legacy Wealth Asset Management sold out of Biogen (BIIB) in Q3 2025, closing a stake of 2,511 shares — an estimated $315K sold.

Legacy Wealth Asset Management first reported a position in BIIB in Q4 2020 and held it in 19 quarters. The position peaked at $1.09M in Q3 2022. 905 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.

  • Legacy Wealth Asset Management reported no remaining Biogen position as of Q3 2025 after selling out during the quarter.
  • Legacy Wealth Asset Management sold 2,511 Biogen shares in Q3 2025, an estimated $315K.
  • Legacy Wealth Asset Management first reported a position in Biogen in Q4 2020 and held it in 19 quarters.
  • Legacy Wealth Asset Management's Biogen position peaked at $1.09M in Q3 2022.
  • 905 funds tracked by Wall St. Rank held Biogen as of Q3 2025.

Based on Legacy Wealth Asset Management's 13F filing for Q3 2025, filed 14 Oct 2025.